+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305474
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Obesity Therapeutics Market is projected to reach USD 12.67 Billion in 2026. It is expected to continue growing at a CAGR of 8.87%, reaching USD 21.21 Billion by 2032.

The anti-obesity therapeutics market is moving from adjunct lifestyle support to evidence-based chronic disease management. World Health Organization data show that adult obesity has more than doubled since 1990, with more than 1 billion people living with obesity globally in 2022, including 890 million adults and 159 million children and adolescents.

Commercial and clinical momentum is being driven by GLP-1 receptor agonists, dual GIP/GLP-1 agonists, cardiometabolic outcome evidence, and payer reassessment of obesity as a long-term medical condition. Clinical data from STEP and SURMOUNT trials, including weight reductions approaching 15% with semaglutide 2.4 mg and more than 20% with tirzepatide in selected trial populations, have reset expectations for obesity pharmacotherapy and intensified focus on durable outcomes, tolerability, and patient persistence.

Transformative Shifts in the Obesity Treatment Landscape

The landscape is being transformed by the shift from short-duration weight-loss products to chronic metabolic therapies that address obesity-related complications. Regulatory approvals of advanced incretin-based obesity medicines, along with expanding real-world use, have accelerated physician adoption, patient demand, and manufacturing scale-up across injectable obesity drugs.

A second major shift is the convergence of obesity care with cardiovascular, renal, hepatic, sleep, and diabetes management. The SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, strengthening the value proposition for payers and health systems. This evidence is pushing anti-obesity therapeutics beyond cosmetic weight reduction toward measurable cardiometabolic risk reduction.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing anti-obesity therapeutics across discovery, clinical development, commercialization, and patient support. AI-enabled molecular modeling, phenotyping, trial recruitment analytics, and safety signal detection are helping accelerate pipeline decisions for incretin-based drugs, oral peptides, amylin analogs, gut hormone combinations, and next-generation metabolic therapies.

In clinical practice, AI can support obesity risk stratification, adherence prediction, dose-titration workflows, and integrated monitoring of cardiometabolic markers such as glycemic control, blood pressure, lipid levels, and liver health indicators. The strongest near-term impact is expected in identifying patients likely to benefit, improving persistence, and supporting evidence generation from real-world data while maintaining privacy protection, bias control, explainability, and regulatory-grade validation.

Key Regional Insights

North America remains the most commercially advanced region due to high obesity prevalence, strong specialist networks, mature reimbursement infrastructure, and rapid uptake of GLP-1-based obesity pharmacotherapy. Europe is expanding through centralized regulatory pathways, national health technology assessments, and increasing recognition of obesity as a chronic disease, although access varies by country and budget impact concerns remain significant. Asia-Pacific is emerging as a major strategic region as China, India, Japan, South Korea, and Australia confront rising metabolic disease burdens, urban lifestyle changes, and expanding private healthcare demand.

Latin America shows meaningful medical need, led by Mexico and Brazil, where obesity and type 2 diabetes are major public health priorities and nutrition-related chronic disease policies are increasingly prominent. The Middle East, especially GCC markets, is adopting premium metabolic therapies amid high diabetes prevalence, advanced private care infrastructure, and growing interest in preventive cardiometabolic medicine. Africa remains earlier-stage for anti-obesity therapeutics, with access constrained by affordability, diagnostic gaps, medicine availability, and health system capacity, even as urbanization and noncommunicable disease burdens increase across the region.

Key Group Insights

The G7 represents the strongest clinical and commercial base for anti-obesity therapeutics because of advanced regulatory systems, specialist prescribing capacity, established pharmaceutical reimbursement channels, and high levels of cardiometabolic disease diagnosis. The European Union is pivotal for market access strategy, as pricing, reimbursement, and health technology assessment decisions influence uptake across member states and shape evidence requirements for long-term obesity pharmacotherapy, including durability, safety, comorbidity reduction, and budget impact management.

BRICS markets are strategically important because they combine large populations, rising obesity prevalence, expanding middle-class demand, and growing local manufacturing capabilities. ASEAN offers a developing opportunity through urbanization, diabetes prevention priorities, and increasing investment in private healthcare systems, while the GCC is characterized by high cardiometabolic disease burden, premium care adoption, and strong demand for advanced metabolic interventions. NATO is not a healthcare market bloc, but its member economies include many high-income systems where supply security, medicine resilience, regulatory coordination, and advanced clinical infrastructure influence therapeutic availability and continuity of care.

Key Country Insights

The United States is the global demand center for anti-obesity therapeutics, supported by regulatory approvals, broad prescriber awareness, employer health benefits, and high obesity prevalence; CDC data reported U.S. adult obesity prevalence at 40.3% during August 2021 to August 2023. Canada is progressing through public and private reimbursement debates and structured health technology evaluation, while Mexico and Brazil face substantial public health need linked to obesity, type 2 diabetes, cardiovascular disease risk, and changing dietary patterns.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are balancing strong clinical demand against budget impact, with Germany and the United Kingdom serving as influential evidence and access markets because of structured assessment processes and specialist clinical networks. France, Italy, and Spain continue to emphasize reimbursement discipline, prescriber guidance, and long-term value demonstration, while Russia remains shaped by local regulatory requirements, affordability considerations, and supply-chain factors.

China and India represent large-scale growth opportunities due to rising obesity rates, expanding diabetes burdens, and increasing investment in metabolic care, although affordability and broad access remain important constraints. Japan and South Korea emphasize metabolic risk management, aging-population health priorities, and clinical evidence standards, supporting measured adoption of obesity pharmacotherapy. Australia combines high disease awareness with structured reimbursement evaluation and established obesity, diabetes, and cardiovascular care pathways, making evidence quality and cost-effectiveness central to access decisions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, renal markers, mobility, and quality-of-life improvements. Payers increasingly require proof of durable benefit, adherence support, appropriate patient selection, and reduced obesity-related complications to justify broader coverage.

Companies should also invest in scalable manufacturing, cold-chain resilience, oral and longer-acting formulations, pharmacovigilance systems, equitable pricing models, and real-world evidence programs. Partnerships with primary care networks, endocrinologists, cardiologists, hepatologists, sleep specialists, digital health providers, and employers can improve diagnosis, treatment persistence, and outcomes in the anti-obesity therapeutics market. Responsible communication, patient education, and continuity-of-care models will be critical to maintaining trust as demand expands.

Research Methodology

This executive summary is based on verified public health, regulatory, and clinical evidence from sources such as the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European Medicines Agency, national health authorities, and peer-reviewed clinical trial publications. Key evidence includes obesity prevalence trends, regulatory approvals, clinical efficacy data, safety findings, cardiometabolic outcomes, and health system access considerations.

The methodology combines secondary research, cross-validation of clinical and regulatory milestones, assessment of regional healthcare structures, and analysis of market access dynamics. Insights are synthesized to reflect current conditions in anti-obesity therapeutics, including GLP-1 receptor agonists, dual incretin agonists, emerging oral therapies, amylin-based approaches, and next-generation metabolic drug pipelines, while avoiding market sizing, market share, and forecasting claims.

Conclusion

Anti-obesity therapeutics are entering a pivotal phase as clinical efficacy, cardiometabolic outcome data, and patient demand converge. The sector is no longer defined only by weight reduction; it is increasingly linked to cardiovascular risk reduction, diabetes management, liver and sleep-related comorbidity care, health system efficiency, and long-term chronic disease management.

Sustained leadership will depend on evidence quality, manufacturing reliability, affordability, equitable access, safety monitoring, and the ability to integrate pharmacotherapy with digital care, nutrition, physical activity, and behavioral support. Organizations that demonstrate durable health outcomes, responsible commercialization, and patient-centered access are best positioned to shape the next decade of obesity treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-Obesity Therapeutics Market, by Drug Class
7.1. Prescription Drugs
7.1.1. GLP 1 Receptor Agonists
7.1.1.1. Semaglutide
7.1.1.2. Liraglutide
7.1.1.3. Tirzepatide
7.1.2. Combination Therapies
7.1.2.1. Phentermine Topiramate
7.1.2.2. Bupropion Naltrexone
7.1.3. Lipase Inhibitors
7.1.4. Sympathomimetic Agents
7.2. Over the Counter Drugs
8. Anti-Obesity Therapeutics Market, by Mechanism of Action
8.1. Centrally Acting Drugs
8.1.1. Appetite Suppressants
8.1.2. Neurotransmitter Modulators
8.2. Peripherally Acting Drugs
8.2.1. Fat Absorption Blockers
8.2.2. Metabolic Enhancers
8.3. Hormonal Based Therapies
9. Anti-Obesity Therapeutics Market, by Route Of Administration
9.1. Oral
9.1.1. Capsules
9.1.2. Tablets
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Subcutaneous
9.3. Transdermal
10. Anti-Obesity Therapeutics Market, by Indication
10.1. Obesity
10.2. Overweight with Comorbidities
10.2.1. Type 2 Diabetes
10.2.2. Cardiovascular Diseases
10.2.3. Hypertension
10.2.4. Dyslipidemia
10.3. Genetic Obesity Disorders
10.4. Hypothalamic Obesity
11. Anti-Obesity Therapeutics Market, by End User
11.1. Hospitals
11.2. Specialty Clinics
11.3. Weight Loss Centers
11.4. Homecare Settings
11.5. Ambulatory Surgical Centers
12. Anti-Obesity Therapeutics Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Asia-Pacific Anti-Obesity Therapeutics Market
14. North America Anti-Obesity Therapeutics Market
15. Latin America Anti-Obesity Therapeutics Market
16. Europe Anti-Obesity Therapeutics Market
17. Middle East Anti-Obesity Therapeutics Market
18. Africa Anti-Obesity Therapeutics Market
19. ASEAN Anti-Obesity Therapeutics Market
20. GCC Anti-Obesity Therapeutics Market
21. European Union Anti-Obesity Therapeutics Market
22. BRICS Anti-Obesity Therapeutics Market
23. G7 Anti-Obesity Therapeutics Market
24. NATO Anti-Obesity Therapeutics Market
25. United States Anti-Obesity Therapeutics Market
26. Canada Anti-Obesity Therapeutics Market
27. Mexico Anti-Obesity Therapeutics Market
28. Brazil Anti-Obesity Therapeutics Market
29. United Kingdom Anti-Obesity Therapeutics Market
30. Germany Anti-Obesity Therapeutics Market
31. France Anti-Obesity Therapeutics Market
32. Russia Anti-Obesity Therapeutics Market
33. Italy Anti-Obesity Therapeutics Market
34. Spain Anti-Obesity Therapeutics Market
35. China Anti-Obesity Therapeutics Market
36. India Anti-Obesity Therapeutics Market
37. Japan Anti-Obesity Therapeutics Market
38. Australia Anti-Obesity Therapeutics Market
39. South Korea Anti-Obesity Therapeutics Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Aardvark Therapeutics
41.2. Altimmune, Inc.
41.3. Amgen Inc.
41.4. Antag Therapeutics ApS
41.5. Ascletis Pharma Inc.
41.6. AstraZeneca PLC
41.7. Boehringer Ingelheim International GmbH
41.8. Currax Pharmaceuticals LLC
41.9. Eli Lilly and Company
41.10. Hanmi Pharm. Co., Ltd.
41.11. Innovent Biologics, Inc.
41.12. Kailera Therapeutics
41.13. Metsera, Inc.
41.14. Novo Nordisk A/S
41.15. Pfizer Inc.
41.16. Rhythm Pharmaceuticals, Inc.
41.17. Roche Holding AG
41.18. Sciwind Biosciences
41.19. Structure Therapeutics Inc.
41.20. Sun Pharmaceutical Industries Ltd.
41.21. Takeda Pharmaceutical Company Limited
41.22. Teva Pharmaceutical Industries Ltd.
41.23. Viking Therapeutics, Inc.
41.24. Zealand Pharma A/S
41.25. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SEMAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SEMAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SEMAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LIRAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LIRAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LIRAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TIRZEPATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TIRZEPATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TIRZEPATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 184. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 185. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 189. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 192. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 210. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 211. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 212. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 213. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 214. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 215. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 216. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 217. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 219. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 220. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 221. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 222. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 225. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 227. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 228. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 229. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 230. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 231. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 232. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 234. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 235. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 236. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 237. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 240. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 241. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 242. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 243. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 244. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 245. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 246. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 247. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 249. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 250. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 251. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 252. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 269. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 270. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 271. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 272. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 273. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 274. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 275. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 276. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 277. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 278. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 279. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 280. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 281. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 282. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 284. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 285. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 286. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 287. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 288. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 289. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 290. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 291. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 292. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 293. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 294. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 295. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 296. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 297. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 298. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 299. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 300. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 301. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 302. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 303. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 304. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 305. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 306. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 307. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 308. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 309. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 310. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 311. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 312. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 314. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 325. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 326. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
TABLE 327. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 328. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 329. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 330. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 331. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 332. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 333. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 334. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 335. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 336. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
TABLE 337. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 338. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 339. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 340. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (US

Companies Mentioned

The companies featured in this Anti-Obesity Therapeutics market report include:
  • Aardvark Therapeutics
  • Altimmune, Inc.
  • Amgen Inc.
  • Antag Therapeutics ApS
  • Ascletis Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Hanmi Pharm. Co., Ltd.
  • Innovent Biologics, Inc.
  • Kailera Therapeutics
  • Metsera, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sciwind Biosciences
  • Structure Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.67 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.21 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032 - Product Image

Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Obesity Market Report and Forecast 2025-2034 - Product Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032 - Product Image

Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032

  • Report
  • 358 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.